SCYX
SCYX
NASDAQ · Pharmaceuticals

Scynexis Inc

$0.89
-0.01 (-0.73%)
As of Mar 25, 5:10 PM ET ·
Financial Highlights (FY 2026)
Revenue
18.37M
Net Income
-7,675,979
Gross Margin
100.0%
Profit Margin
-41.8%
Rev Growth
+59.4%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 100.0% 100.0% 42.8% 42.8%
Operating Margin -78.0% -70.2% 27.4% 27.9%
Profit Margin -41.8% -39.7% 28.0% 22.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 18.37M 11.53M 9.68M 11.00M
Gross Profit 18.37M 11.53M 4.14M 4.71M
Operating Income -14,334,658 -8,095,627 2.65M 3.07M
Net Income -7,675,979 -4,335,078 2.71M 2.47M
Gross Margin 100.0% 100.0% 42.8% 42.8%
Operating Margin -78.0% -70.2% 27.4% 27.9%
Profit Margin -41.8% -39.7% 28.0% 22.5%
Rev Growth +59.4% +59.4% +15.5% +17.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 3.72M 4.09M
Total Equity 23.32M 24.16M
D/E Ratio 0.16 0.17
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -9,185,351 -5,475,704 3.39M 3.79M
Free Cash Flow 1.90M 2.29M